Cumulative meta-analysis of epidermal growth factor receptor- @entity4149 kinase inhibitors as first-line therapy in metastatic XXXX .

@entity1 @entity137 @entity1910 @entity470 @entity294 @entity1149 @entity4149 @entity902
We carried out a meta-analysis to evaluate the benefit of epidermal growth factor- @entity4149 kinase inhibitors ( @entity470 ) over the standard first-line @entity902 -based chemotherapy for metastatic @entity1149 ( @entity1149 ). Studies that were considered eligible included controlled prospective randomized phase III studies in @entity1 with @entity1149 stages IIIB or IV. These @entity1 received standard first-line @entity902 -based chemotherapy or @entity470 -TKI; overall survival and progression-free survival (PFS) with adequate data were available to calculate and estimate the hazard ratio (HR) with a confidence interval (CI) of 95%. Eight studies were identified that compared @entity470 -TKI versus standard first-line @entity902 -based chemotherapy to treat @entity1149 in 2962 @entity1 . @entity1 receiving @entity470 showed significantly longer PFS [HR=0.266 (95% CI=0.20-0.35), P<0.0001]. No significant difference in overall survival [HR=0.946 (95% CI=0.35-2.53), P=0.912] was observed between the groups. The cumulative meta-analysis of the studies showed that, since 2011 (OPTIMAL study), the PFS benefit in the @entity470 arm was statistically significantly longer. @entity137 values greater than or equal to 3 in the most prevalent @entity470 -TKI group included @entity1910 , @entity294 , and increased aminotransferase. @entity470 -TKI treatment significantly extends PFS, with acceptable @entity137 than @entity902 -based chemotherapy. Thus, they should be considered as the first choice in the first-line treatment for @entity1 with @entity1149 and with the @entity470 mutation.
